Warner Pharmaceuticals announced that Hunan Warner Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received indoline green's “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the State Drug Administration. The API has been approved for use in domestic formulations, and the result of the joint review and approval with the formulation is A. Indoline green is a raw material for injectable preparations such as indocyanine green. It is mainly used for liver disease diagnosis, choroidal angiography, etc. This approval will further enrich the company's product line and enhance its core competitiveness. There is uncertainty about the production and sales time of this variety and its impact on performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.